PRESS DIGEST - Wall Street Journal - Jan 24
Jan 24 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
Dec 19 Catalyst Biosciences Inc :
* Catalyst Biosciences Inc - drug product fill-finish manufacturing services agreement for marzeptacog alfa (activated) for clinical trial applications
* Catalyst Biosciences Inc - has secured all rights to manufacturing process for Marzeptacog Alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer
* Catalyst Biosciences Inc - has signed a drug product fill-finish manufacturing services agreement with symbiosis pharmaceutical services limited
* Catalyst Biosciences Inc - prepared to initiate an efficacy study in 2017 for marzeptacog alpha (activated) Source text for Eikon: Further company coverage:
KUALA LUMPUR, Jan 24 Malaysia's AirAsia X Bhd on Tuesday said it has become Asia's first low-cost carrier to receive approval to operate scheduled passenger flights to any destination within the United States.
TOKYO, Jan 24 Japanese stocks declined on Tuesday as U.S. President Donald Trump's protectionist policy stance rattled investors while banks led the losses on sliding U.S. and global bond yields.